VantAI and BMS Partner to Expedite Molecular Glue Drug Discovery Through Artificial Intelligence
Shots:
- VantAI and BMS have signed a strategic collaboration for the discovery of new molecular glues for targeting therapeutic areas of interest
- VantAI will receive ~$674M in milestone payments which include discovery, development, clinical, regulatory, and sales plus tiered royalties with an option of expansion to additional therapeutic programs
- The collaboration will utilize BMS’ expertise in targeted protein degradation for the discovery and development of new small molecules and VantAI’s geometric deep learning technology, Protein-Contact-First (PCF) approach that makes the complex chemical design challenge simple to produce solutions with optimized parameters like potency, selectivity, and molecule size
Ref: VantAI | Image: VantAI
Related News:- Boehringer Ingelheim Entered into a Research Agreement with VantAI to Identify Novel Protein Degraders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
